Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Incyte Meets 80-Plus Relative Strength Rating Benchmark

When putting together your watch list, focus on stocks with an 80 or higher RS Rating. Incyte is one stock that just reached the mark, now earning a score of 81.

This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.

History reveals that the best-performing stocks often have an RS Rating north of 80 as they begin their biggest climbs.

Risk Management In The Stock Market: How Much Money To Invest Now

Incyte is working on a consolidation with an 83.95 entry. See if the stock can break out in volume at least 40% above average.

Earnings growth fell in the most recent quarter from 0% to -3%. But revenue gains moved higher, from 9% to 24%.

Incyte earns the No. 59 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Improved Technical Action?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.